MET and non-small cell lung carcinoma: The most extensively studied ALK inhibitor in neuroblastoma, crizotinib, is a small molecule competitive inhibitor of ALK and MET kinase activity and is FDA approved for use in adult patients with ALK-translocated non-small cell lung cancer (NSCLC).